Leading figures from across the pharmaceutical industry have joined forces to launch Adeptio Pharmaceuticals Ltd., an organisation which combines the experience and expertise available to a large pharmaceutical company with the agility of a small specialist pharmaceutical company.
Adeptio Pharmaceuticals Ltd. is a well-funded, privately owned company with an industry renowned Board of Directors including industry icons such as Henry Wendt lll CBE (former Chairman SmithKline Beecham plc, founder and former Chairman of Global Healthcare Partners), Handel Evans (co-founder and former Chairman of Marketing Services Inc., co-founder and senior executive of IMS International Inc.) and Mark Evans (former CEO of Cambridge Laboratories). Other Non Board Investors include individuals such as Bernard Taylor (co-founder and former Executive of Chairman Medeva plc) who also brings a lifetime of experience within the pharmaceutical industry. Ian Montague CEO has over 20 years’ experience in the pharmaceutical industry with companies such as Abbott Laboratories and Roche Pharmaceuticals, most recently holding the position of Business Unit Director for Northern Europe at Valeant Pharmaceuticals Ltd.
Focused on the research and development of drug delivery systems designed and developed to meet the needs of patients and specialist physicians, Adeptio Pharmaceuticals Ltd. brings its team’s wealth of experience to address long term treatment challenges.
The company targets established niche and specialist therapeutic markets by designing and developing innovative products based on already established active pharmaceutical ingredients to address long term treatment challenges.. The Board brings its in-depth and wide-ranging knowledge in a variety of sectors including neurology, wound care and OTC dermatology and has extensive experience of managing drug development teams, while the Management team has a strong background in all aspects of managing a product life span, including strategic pipeline development, regulatory affairs (MHRA, FDA and Orphan Drug), and has a record of having successfully launched many products in the EU, US and globally. In addition the team brings extensive experience in the areas of operations, finance and international marketing.
Ian Montague, CEO of Adeptio Pharmaceuticals Ltd. commented:
‘Adeptio Pharmaceuticals Ltd. has ambitious plans and the first projects are already in progress and running to schedule. Several other opportunities are currently being evaluated by the Management team and we anticipate initiating at least one of these in 2012.
‘Adeptio Pharmaceuticals Ltd. has the ability to accelerate product time to market launch. We aim to reduce the inherent risks of product development and secure long term protection of intellectual property, thus creating and adding value through the research and development process.
‘Our Management team has the depth and breadth of experience required to manage a product from pre-clinical development through to market and all have a proven track record of this. It is this combination of Board and Management know-how which gives Adeptio Ltd. the strongest possible foundation. We are taking the vast experience of these two elements to create a forward thinking, ground-breaking company. The industry leaders we have on board give us an incredibly strong starting point and we look forward to helping shape the future of the pharmaceutical industry.’
For more information:
Last updated on: 29/05/2012 14:06:48